

CITATION REPORT

List of articles citing

Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients

DOI: 10.1161/circheartfailure.112.000162

Circulation: Heart Failure, 2013, 6, 395-402.

Source: <https://exaly.com/paper-pdf/56484030/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
258	Variable effects of anti-diabetic drugs in animal models of myocardial ischemia and remodeling: a translational perspective for the cardiologist. 2013 , 169, 385-93		11
257	Metformin in Diabetic Patients with Heart Failure: Safe and Effective?. 2013 , 7, 417-422		17
256	Diabetes, impaired fasting glucose, and heart failure: it's not all about the sugar. <i>European Journal of Heart Failure</i> , 2014 , 16, 1153-6	12.3	16
255	Association of impaired fasting glucose, diabetes and their management with the presentation and outcome of peripheral artery disease: a cohort study. <i>Cardiovascular Diabetology</i> , 2014 , 13, 147	8.7	28
254	The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies. 2014 , 14, 129		48
253	[Complementary treatment of acute heart failure in patients with diabetes, chronic obstructive pulmonary disease or anemia]. 2014 , 142 Suppl 1, 59-65		3
252	Therapieoptionen des Diabetes mellitus Typ 2 bei hospitalisierten Patienten. 2014 , 9, R9-R20		
251	Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis. 2014 , 42, 420-32		122
250	Impact of diabetes mellitus on the clinical response to cardiac resynchronization therapy in elderly people. 2014 , 7, 362-8		42
249	Metformin: from mechanisms of action to therapies. 2014 , 20, 953-66		715
248	Stem cell therapy to treat heart ischaemia: implications for diabetes cardiovascular complications. 2014 , 14, 554		8
247	Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. 2014 , 130, 1579-88		479
246	[Cardiovascular preventive recommendations]. 2014 , 46 Suppl 4, 3-15		4
245	Standards of medical care in diabetes--2014. <i>Diabetes Care</i> , 2014 , 37 Suppl 1, S14-80	14.6	3373
244	Association between type-2 diabetes mellitus and post-discharge outcomes in heart failure patients: findings from the RICA registry. 2014 , 104, 410-9		39
243	Mortality risk with sulphonylureas compared to metformin. 2014 , 16, 885-90		17
242	Successful metabolic adaptations leading to the prevention of high fat diet-induced murine cardiac remodeling. <i>Cardiovascular Diabetology</i> , 2015 , 14, 127	8.7	13

241	Management of Noncardiac Comorbidities in Chronic Heart Failure. 2015 , 33, 300-15		22
240	Risk patterns in drug safety study using relative times by accelerated failure time models when proportional hazards assumption is questionable: an illustrative case study of cancer risk of patients on glucose-lowering therapies. 2015 , 14, 382-94		3
239	Variations in Metformin Prescribing for Type 2 Diabetes. 2015 , 28, 777-84		4
238	Do the Effects of Secondary Prevention of Cardiovascular Events in PAD Patients Differ from Other Atherosclerotic Disease?. <i>International Journal of Molecular Sciences</i> , 2015 , 16, 14477-89	6.3	8
237	Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy. 2015 , 385, 2107-17		188
236	(8) Cardiovascular disease and risk management. <i>Diabetes Care</i> , 2015 , 38 Suppl, S49-57	14.6	206
235	Pharmacologic treatment of type 2 diabetes: oral medications. 2015 , 49, 540-56		54
234	Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets. 2015 , 89, 1401-38		337
233	Glycemia Lowering and Risk for Heart Failure: Recent Evidence from Studies of Dipeptidyl Peptidase Inhibition. <i>Circulation: Heart Failure</i> , 2015 , 8, 819-25	7.6	11
232	Oral hypoglycemic agents and the heart failure conundrum: Lessons from and for outcome trials. 2015 , 25, 697-705		9
231	Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. 2015 , 36, 1718-27, 1727a-1727c		294
230	Managing comorbidities in patients with chronic heart failure: first, do no harm. 2015 , 15, 171-84		10
229	Targeting metabolic disturbance in the diabetic heart. <i>Cardiovascular Diabetology</i> , 2015 , 14, 17	8.7	37
228	Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. 2015 , 385, 2067-76		551
227	Lactic Acidosis in a Patient with Type 2 Diabetes Mellitus. 2015 , 10, 1476-83		13
226	Consider safety when managing co-morbid conditions in heart failure patients. 2015 , 31, 397-401		
225	Approach to Chronic Kidney Disease in the Diabetic Patient. 2015 , 523-533		
224	Cardiac Resynchronization Therapy Outcomes in Type 2 Diabetic Patients: Role of MicroRNA Changes. 2016 , 2016, 7292564		21

223	Noninsulin Antidiabetic Drugs for Patients with Type 2 Diabetes Mellitus: Are We Respecting Their Contraindications?. 2016 , 2016, 7502489		13
222	Kardiale Effekte aktueller Antidiabetika. 2016 , 16, 38-42		
221	Is diabetes still a state of premature cardiovascular death?. 2016 , 33, 285-290		1
220	Insulin Signaling and Heart Failure. 2016 , 118, 1151-69		197
219	Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes. 2016 , 118, 1830-43		46
218	Treating Diabetes in Patients with Heart Failure: Moving from Risk to Benefit. 2016 , 13, 111-8		3
217	Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial. <i>Cardiovascular Diabetology</i> , 2016 , 15, 57	8.7	24
216	Diabetes and oral therapies: A review of oral therapies for diabetes mellitus. 2016 , 11, 317-329		20
215	[Modern antihyperglycaemic agents--what is the patient benefit?]. 2016 , 158, 45-8		
214	Prescribing attitudes, behaviors and opinions regarding metformin for patients with diabetes: a focus group study. 2016 , 7, 220-8		9
213	Metformin: Candidate host-directed therapy for tuberculosis in diabetes and non-diabetes patients. 2016 , 101S, S69-S72		35
212	[Not Available]. 2016 , 48 Suppl 1, 4-26		5
211	Is the Use of DPP-4 Inhibitors Associated With an Increased Risk for Heart Failure? Lessons From EXAMINE, SAVOR-TIMI 53, and TECOS. <i>Diabetes Care</i> , 2016 , 39 Suppl 2, S210-8	14.6	17
210	Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association. 2016 , 134, e32-69		210
209	Antihyperglycemic Medication Use Among Medicare Beneficiaries With Heart Failure, Diabetes Mellitus, and Chronic Kidney Disease. <i>Circulation: Heart Failure</i> , 2016 , 9,	7.6	16
208	Cardiovascular effects of anti-diabetes drugs. 2016 , 15, 1239-57		11
207	Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. 2016 , 12, 566-92		205
206	Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations. 2016 , 133, 2459-502		520

205	Assessing Risks of Glucose Lowering Therapy in Heart Failure: Should We Rely on Post-hoc Analyses?. 2016 , 10, 1		
204	Metformin: A Hopeful Promise in Aging Research. 2016 , 6, a025932		82
203	8. Cardiovascular Disease and Risk Management. <i>Diabetes Care</i> , 2016 , 39 Suppl 1, S60-71	14.6	196
202	Approach to diabetes management in patients with CVD. 2016 , 26, 165-79		28
201	[Cardiovascular safety concerns of glucose-lowering drugs]. 2017 , 159, 62-66		
200	Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2017 , 16, 18	8.7	34
199	Metformin effects on the heart and the cardiovascular system: A review of experimental and clinical data. 2017 , 27, 657-669		123
198	A story of metformin-butyrate synergism to control various pathological conditions as a consequence of gut microbiome modification: Genesis of a wonder drug?. 2017 , 117, 103-128		39
197	Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease: A Systematic Review. 2017 , 166, 191-200		155
196	Treating Disease Mechanisms in Patients With Heart Failure and Diabetes Mellitus. 2017 , 14, 445-453		5
195	Pathogenesis, Clinical Features and Treatment of Diabetic Cardiomyopathy. <i>Advances in Experimental Medicine and Biology</i> , 2018 , 1067, 197-217	3.6	35
194	Metformin attenuates ER stress-induced mitochondrial dysfunction. 2017 , 190, 40-50		43
193	[Combination of oral antidiabetic drugs: What fits together?]. 2017 , 159, 47-52		
192	Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus. <i>Postgraduate Medicine</i> , 2017 , 129, 811-821	3.7	32
191	Metformin Use in Practice: Compliance With Guidelines for Patients With Diabetes and Preserved Renal Function. <i>Clinical Diabetes</i> , 2017 , 35, 154-161	2.9	6
190	Cardiovascular Safety of Antidiabetic Drugs in the Hospital Setting. 2017 , 17, 64		1
189	Mitochondria-Targeted Triphenylphosphonium-Based Compounds: Syntheses, Mechanisms of Action, and Therapeutic and Diagnostic Applications. 2017 , 117, 10043-10120		654
188	Management of newly treated diabetes in Medicare beneficiaries with and without heart failure. 2017 , 40, 38-45		11

187	Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes. <i>European Journal of Heart Failure</i> , 2017 , 19, 43-53	12.3	76
186	Metformin, beyond an insulin sensitizer, targeting heart and pancreatic β cells. 2017 , 1863, 1984-1990		51
185	Editorial commentary: Anti-glycemic drugs and heart failure-A new era. 2017 , 27, 152-154		
184	The impact of glucose-lowering medications on cardiovascular disease. 2018 , 7, 13-17		
183	Does metformin exposure before ICU stay have any impact on patients' outcome? A retrospective cohort study of diabetic patients. 2017 , 7, 116		13
182	2018 consensus of the Taiwan Society of Cardiology and the Diabetes Association of Republic of China (Taiwan) on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases. 2018 , 81, 189-222		14
181	The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventions. <i>Heart Failure Reviews</i> , 2018 , 23, 303-323	5	27
180	Targeting Other Modifiable Risk Factors for the Prevention of Heart Failure: Diabetes, Smoking, Obesity, and Inactivity. 2018 , 12, 1		
179	Glucose-Lowering Therapies and Heart Failure in Type 2 Diabetes Mellitus: Mechanistic Links, Clinical Data, and Future Directions. 2018 , 137, 1060-1073		20
178	Treatment of Diabetes in People With Heart Failure. 2018 , 42 Suppl 1, S196-S200		17
177	Effect of glucose-lowering therapies on heart failure. 2018 , 15, 282-291		34
176	The influence of anti-hyperglycemic drug therapy on cardiovascular and heart failure outcomes in patients with type 2 diabetes mellitus. <i>Heart Failure Reviews</i> , 2018 , 23, 445-459	5	4
175	Is metformin beneficial for heart failure in patients with type 2 diabetes?. 2018 , 136, 168-170		19
174	Heart Failure: Epidemiology, Pathophysiology, and Management of Heart Failure in Diabetes Mellitus. 2018 , 47, 117-135		16
173	Management of diabetes in older adults. 2018 , 28, 206-218		30
172	Diabetes and the cardiovascular system. 2018 , 141-170		
171	Heart Failure: The Most Important, Preventable, and Treatable Cardiovascular Complication of Type 2 Diabetes. <i>Diabetes Care</i> , 2018 , 41, 11-13	14.6	49
170	Heart failure risk and major cardiovascular events in diabetes: an overview of within-group differences in non-insulin antidiabetic treatment. <i>Heart Failure Reviews</i> , 2018 , 23, 469-479	5	4

169	Exploring heart failure events in contemporary cardiovascular outcomes trials in type 2 diabetes mellitus. 2018 , 16, 123-131		
168	Worsening Heart Failure During the Use of DPP-4 Inhibitors: Pathophysiological Mechanisms, Clinical Risks, and Potential Influence of Concomitant Antidiabetic Medications. 2018 , 6, 445-451		42
167	Reply: Diabetes and Heart Failure: Are We in the Right Direction to Find the Right Morsel for Success?. 2018 , 6, 270-271		1
166	Metformin in heart failure patients. 2018 , 70, 175-176		11
165	Diabetes and Adipocyte Dysfunction. 2018 , 69-84		
164	Safety of diabetes drugs in patients with heart failure. 2018 , 218, 98-107		
163	Safety of diabetes drugs in patients with heart failure. 2018 , 218, 98-107		
162	Still sour about lactic acidosis years later: role of metformin in heart failure. <i>Heart Failure Reviews</i> , 2018 , 23, 347-353	5	6
161	Pharmacotherapy of type 2 diabetes: An update. <i>Metabolism: Clinical and Experimental</i> , 2018 , 78, 13-42	12.7	103
160	Echocardiographic feature of diabetic cardiomyopathy: where are we now?. 2018 , 8, 47-56		18
159	. 2018 ,		1
158	The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments. 2018 , 14, 1287-1302		41
157	Physical Exercise and Its Protective Effects on Diabetic Cardiomyopathy: What Is the Evidence?. 2018 , 9, 729		15
156	Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology. 2018 , 39, 4243-4254		113
155	Metabolic Effects of Metformin in the Failing Heart. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	45
154	Epicardial Adipose Tissue May Mediate Deleterious Effects of Obesity and Inflammation on the Myocardium. 2018 , 71, 2360-2372		186
153	Insuffisance cardiaque et diabète : la nouvelle pandémie sous-estimée, mal connue, qui ne peut être ignorée plus longtemps. 2018 , 12, 182-189		
152	Patterns of glucose-lowering medication use in patients with type 2 diabetes and heart failure. Insights from the Diabetes Collaborative Registry (DCR). 2018 , 203, 25-29		15

151	Assessing the incidence of acidosis in patients receiving metformin with and without risk factors for lactic acidosis. 2018 , 9, 179-190		7
150	Acute vs cumulative benefits of metformin use in patients with type 2 diabetes and heart failure. 2018 , 20, 2653-2660		8
149	The treatment of type 2 diabetes in heart failure. 2018 , 35, 123-126		2
148	Antihyperglycemic Therapies to Treat Patients With Heart Failure and Diabetes Mellitus. 2018 , 6, 813-822		20
147	: Type 2 Diabetes and Readmission for Heart Failure. 2018 , 12, 1179546818779588		6
146	Diabetes-related cardiomyopathy: The sweet story of glucose overload from epidemiology to cellular pathways. 2019 , 45, 238-247		27
145	Management of patients with diabetes and heart failure with reduced ejection fraction: An international comparison. 2019 , 21, 261-266		6
144	Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 Trial. 2019 , 140, 1004-1014		40
143	Cardiac Insulin Resistance in Heart Failure: The Role of Mitochondrial Dynamics. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	19
142	Saudi Heart Association (SHA) guidelines for the management of heart failure. 2019 , 31, 204-253		5
141	A Review of Cardiovascular Outcomes Trials of Glucose-Lowering Therapies and Their Effects on Heart Failure Outcomes. 2019 , 132, S13-S20		1
140	Metformin Use Is Associated With a Lower Risk of Hospitalization for Heart Failure in Patients With Type 2 Diabetes Mellitus: a Retrospective Cohort Analysis. 2019 , 8, e011640		27
139	Metformin lactic acidosis: Should we still be afraid?. 2019 , 157, 107879		10
138	Glucose-lowering drugs and heart failure: implications of recent cardiovascular outcome trials in type 2 diabetes. 2019 , 157, 107835		6
137	Drugs That Ameliorate Epicardial Adipose Tissue Inflammation May Have Discordant Effects in Heart Failure With a Preserved Ejection Fraction as Compared With a Reduced Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2019 , 25, 986-1003	3.3	13
136	Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. 2019 , 140, e294-e324		168
135	Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America. <i>Journal of Cardiac Failure</i> , 2019 , 25, 584-619	3.3	30
134	Effects of sodium glucose cotransporter type 2 inhibitors on heart failure. 2019 , 21 Suppl 2, 19-23		16

133	Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline. 2019 , 104, 1520-1574	146
132	Heart failure in the patient with diabetes: Epidemiology, aetiology, prognosis, therapy and the effect of glucose-lowering medications. 2019 , 21, 1277-1290	43
131	Diuretic treatment of the patient with diabetes and heart failure. Role of SGLT2 inhibitors and similarities with carbonic anhydrase inhibitors. 2019 , 219, 208-217	1
130	A Review of Cardiovascular Outcomes Trials of Glucose-Lowering Therapies and Their Effects on Heart Failure Outcomes. 2019 , 124 Suppl 1, S12-S19	8
129	Physiological monitoring of the complex multimorbid heart failure patient - diabetes and monitoring glucose control. 2019 , 21, M20-M24	
128	Diuretic treatment of the patient with diabetes and heart failure. Role of SGLT2 inhibitors and similarities with carbonic anhydrase inhibitors. 2019 , 219, 208-217	2
127	Heart Failure in Type 2 Diabetes Mellitus. 2019 , 124, 121-141	210
126	Management of Diabetes Mellitus. 2019 , 113-177	
125	A closer look at heart failure in patients with concurrent diabetes mellitus using glucose lowering drugs. 2019 , 12, 45-52	3
124	Management of Comorbidities in Heart Failure. 2020 , 687-696.e2	
123	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. 2020 , 41, 255-323	1360
122	Approach to Chronic Kidney Disease in the Diabetic Patient. 2020 , 831-847	
121	Association between long-term prescription of metformin and the progression of heart failure with preserved ejection fraction in patients with type 2 diabetes mellitus and hypertension. 2020 , 306, 140-145	12
120	A randomised, double-blind, placebo-controlled trial of metformin on myocardial efficiency in insulin-resistant chronic heart failure patients without diabetes. <i>European Journal of Heart Failure</i> , 2020 , 22, 1628-1637	12.3 23
119	Strategies of Unloading the Failing Heart from Metabolic Stress. 2020 , 133, 290-296	6
118	European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure. <i>European Journal of Heart Failure</i> , 2020 , 22, 196-213	12.3 85
117	Impact of diabetes on mortality and rehospitalization in acute heart failure patients stratified by ejection fraction. <i>ESC Heart Failure</i> , 2020 , 7, 297-305	3.7 4
116	The right place for metformin today. 2020 , 159, 107946	16

115	Myocardial glucotoxicity: Mechanisms and potential therapeutic targets. <i>Archives of Cardiovascular Diseases</i> , 2020 , 113, 736-748	2.7	6
114	Where Does Metformin Stand in Modern Day Management of Type 2 Diabetes?. 2020 , 13,		6
113	Metformin treatment in heart failure with preserved ejection fraction: a systematic review and meta-regression analysis. <i>Cardiovascular Diabetology</i> , 2020 , 19, 124	8.7	24
112	Distribution of traditional Chinese medicine syndromes in type 2 diabetes mellitus with chronic heart failure: A clinical study. 2020 , 99, e21091		
111	Potentially Inappropriate Prescriptions in Heart Failure with Reduced Ejection Fraction (PIP-HFrEF). 2020 ,		6
110	Repurposing Antidiabetic Drugs for Cardiovascular Disease. 2020 , 11, 568632		6
109	The potential role of metformin in the treatment of patients with pancreatic neuroendocrine tumors: a review of preclinical to clinical evidence. 2020 , 13, 1756284820927271		3
108	Heart failure documentation in outpatients with diabetes and volume overload: an observational cohort study from the Diabetes Collaborative Registry. <i>Cardiovascular Diabetology</i> , 2020 , 19, 212	8.7	2
107	Diabetic cardiomyopathy.. 2022 , 222, 100-111		0
106	Guía ESC 2019 sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes (EASD). <i>Revista Espanola De Cardiologia</i> , 2020 , 73, 404.e1-404.e59		
105	Metformin Indications, Dosage, Adverse Reactions, and Contraindications. 2020 ,		0
104	Metformin and heart failure-related outcomes in patients with or without diabetes: a systematic review of randomized controlled trials. <i>Heart Failure Reviews</i> , 2021 , 26, 1437-1445	5	14
103	Promising roles of sodium-glucose cotransporter 2 inhibitors in heart failure prevention and treatment. 2020 , 11, 252-260		4
102	Heart Failure With Type 2 Diabetes Mellitus: Association Between Antihyperglycemic Agents, Glycemic Control, and Ejection Fraction. 2020 , 11, 448		1
101	2020 Consensus of Taiwan Society of Cardiology on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases. 2020 , 83, 587-621		3
100	Cardiovascular Safety and Benefits of Noninsulin Antihyperglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus-Part 1. 2020 , 28, 177-189		3
99	The Vicious Circle of Left Ventricular Dysfunction and Diabetes: From Pathophysiology to Emerging Treatments. 2020 , 105,		3
98	Metformin: An old drug against old age and associated morbidities. 2020 , 160, 108025		32

97	Prescription patterns of diabetes medications influencing clinical outcomes of heart failure patients with reduced ejection fraction. <i>ESC Heart Failure</i> , 2020 , 7, 604-615	3.7	4
96	Use of sodium-glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure. <i>European Journal of Heart Failure</i> , 2020 , 22, 604-617 ^{1,2,3}		22
95	Reviews on New Drug Targets in Age-Related Disorders. <i>Advances in Experimental Medicine and Biology</i> , 2020 ,	3.6	2
94	Second revolution in cardiovascular prevention. 2020 , 83, 327-336		3
93	Metformin and myocardial ischemia and reperfusion injury: Moving toward "prime time" human use?. 2021 , 229, 1-4		3
92	Management of patients with chronic heart failure and type 2 diabetes mellitus: the SCODIAC-II study. 2021 , 16, 895-903		3
91	Evolution of Myocardial Dysfunction in Asymptomatic Patients at Risk of Heart Failure. 2021 , 14, 350-361		2
90	How Diabetes and Heart Failure Modulate Each Other and Condition Management. 2021 , 37, 595-608		7
89	Diagnosis, prevention, and treatment of cardiovascular diseases in people with type 2 diabetes and prediabetes: a consensus statement jointly from the Japanese Circulation Society and the Japan Diabetes Society. 2021 , 12, 1-51		5
88	Glucose-lowering pharmacotherapies in Chinese adults with type 2 diabetes and cardiovascular disease or chronic kidney disease. An expert consensus reported by the Chinese Diabetes Society and the Chinese Society of Endocrinology. 2021 , 37, e3416		4
87	Morphological characteristics in diabetic cardiomyopathy associated with autophagy. 2021 , 77, 30-40		4
86	Optimizing Management of Type 2 Diabetes and Its Complications in Patients With Heart Failure. <i>Clinical Diabetes</i> , 2021 , 39, 105-116	2.9	
85	Expect the Unexpected in the Medical Treatment of Heart Failure with Reduced Ejection Fraction: between Scientific Evidence and Clinical Wisdom. 3,		0
84	Diabetes Mellitus. 2021 , 375-390		
83	Current Status and Potential Therapeutic Strategies for Using Non-coding RNA to Treat Diabetic Cardiomyopathy. 2020 , 11, 612722		2
82	Diabetes and Heart Failure. 2021 , 3, 21		
81	Metformin – ein Opfer des eigenen Erfolges?. 2021 , 17, 218-219		
80	Cardiometabolism as an Interlocking Puzzle between the Healthy and Diseased Heart: New Frontiers in Therapeutic Applications. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	5

79	NETosis as a Pathogenic Factor for Heart Failure. 2021 , 2021, 6687096		7
78	The Current and Potential Therapeutic Use of Metformin-The Good Old Drug. 2021 , 14,		15
77	Diabetes Management in Patients with Heart Failure. 2021 , 45, 158-172		2
76	The Association Between Metformin Treatment and Outcomes in Type 2 Diabetes Mellitus Patients With Heart Failure With Preserved Ejection Fraction: A Retrospective Study. 2021 , 8, 648212		2
75	Chronic metformin treatment decreases cardiac injury during ischemia-reperfusion by attenuating endoplasmic reticulum stress with improved mitochondrial function. 2021 , 13, 7828-7845		6
74	Narrative review: the holy grail: update on pharmacotherapy for heart failure with preserved ejection fraction. 2021 , 9, 523		1
73	Diabetes and Heart Failure. 2021 , 22, 12-20		
72	Management of noncardiovascular comorbidities in patients with heart failure with reduced ejection fraction. 2021 , 41, 537-545		0
71	AMP-activated protein kinase: A remarkable contributor to preserve a healthy heart against ROS injury. <i>Free Radical Biology and Medicine</i> , 2021 , 166, 238-254	7.8	11
70	Human umbilical cord mesenchymal stem cells in type 2 diabetes mellitus: the emerging therapeutic approach. 2021 , 385, 497-518		2
69	MPEG-PCL Nanomicelles Platform for Synergistic Metformin and Chrysin Delivery to Breast Cancer in Mice. 2021 ,		2
68	The Diabetic Cardiomyopathy: The Contributing Pathophysiological Mechanisms. 2021 , 8, 695792		16
67	Treating heart failure in patients with diabetes: The view of the cardiologist. 2021 , 176, 108852		1
66	Safety and effectiveness of metformin in patients with reduced renal function: A systematic review. 2021 , 23, 2035-2047		1
65	Glucose-lowering Drugs and Hospitalization for Heart Failure: A Systematic Review and Additive-effects Network Meta-analysis With More Than 500 000 Patient-years. 2021 , 106, 3060-3067		1
64	The Mystery of Diabetic Cardiomyopathy: From Early Concepts and Underlying Mechanisms to Novel Therapeutic Possibilities. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	6
63	Autophagy in the diabetic heart: A potential pharmacotherapeutic target in diabetic cardiomyopathy. 2021 , 68, 101338		20
62	Which drug is best for a patient with type 2 diabetes and heart failure?. 2021 , 34, 49-52		

61	CARDIOVASCULAR EFFECTS OF NON-INSULIN GLUCOSE-LOWERING AGENTS: A COMPREHENSIVE REVIEW OF TRIAL EVIDENCE AND POTENTIAL CARDIOPROTECTIVE MECHANISMS. <i>Cardiovascular Research</i> , 2021 ,	9.9	5
60	Lactate and Myocardial Energy Metabolism. 2021 , 12, 715081		6
59	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. 2021 , 42, 3599-3726		875
58	Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents. <i>Cardiovascular Diabetology</i> , 2021 , 20, 175	8.7	1
57	JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure. <i>Journal of Cardiac Failure</i> , 2021 , 27, 1404-1444	3.3	8
56	JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure. <i>Circulation Journal</i> , 2021 , 85, 2252-2291	2.9	8
55	Heart Failure in Type 1 Diabetes: A Complication of Concern? A Narrative Review. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	0
54	Diabetic Cardiomyopathy: Clinical and Metabolic Approach. <i>Current Vascular Pharmacology</i> , 2021 , 19, 487-498	3.3	1
53	Developmental phenotypic and transcriptomic effects of exposure to nanomolar levels of metformin in zebrafish. <i>Environmental Toxicology and Pharmacology</i> , 2021 , 87, 103716	5.8	1
52	The Use of Metformin to Increase the Human Healthspan. <i>Advances in Experimental Medicine and Biology</i> , 2020 , 1260, 319-332	3.6	20
51	Targeting perivascular and epicardial adipose tissue inflammation: therapeutic opportunities for cardiovascular disease. <i>Clinical Science</i> , 2020 , 134, 827-851	6.5	22
50	Diabetes management in older people: a focus on cardiovascular risk reduction. <i>Postgraduate Medicine</i> , 2017 , 129, 169-177	3.7	2
49	Diagnosis, Prevention, and Treatment of Cardiovascular Diseases in People With Type 2 Diabetes and Prediabetes - A Consensus Statement Jointly From the Japanese Circulation Society and the Japan Diabetes Society. <i>Circulation Journal</i> , 2020 , 85, 82-125	2.9	7
48	Diabetes mellitus type 2 in adults. <i>Diabetes Mellitus</i> , 2020 , 23, 4-102	1.6	9
47	Chronic heart failure and type 2 diabetes: state of the problem. <i>Russian Journal of Cardiology</i> , 2020 , 25, 3858	1.3	4
46	[Type 2 Diabetes Mellitus and Heart Failure: Innovative Possibilities for Management of Prognosis]. <i>Kardiologiya</i> , 2019 , 59, 76-87	1.5	6
45	Intersection Between Diabetes and Heart Failure: Is SGLT2i the "One Stone for Two Birds" Approach?. <i>Current Cardiology Reports</i> , 2021 , 23, 171	4.2	0
44	The role of hyperglycaemia in the development of diabetic cardiomyopathy. <i>Archives of Cardiovascular Diseases</i> , 2021 , 114, 748-760	2.7	5

43	<i></i>Low Dose</i> Irbesartan Has a Renoprotective Effect as High Dose Ramipril in Diabetic Rats Treated with Insulin. <i>Open Journal of Endocrine and Metabolic Diseases</i> , 2015 , 05, 149-161	0.1	
42	Heart failure in diabetes: effects of anti-hyperglycemic drug therapy. <i>Diabetes Mellitus</i> , 2016 , 19, 229-236	6.6	1
41	EMPA-REG OUTCOME and reduction of the risk of heart failure in patients with diabetes. <i>Interni Medicina Pro Praxi</i> , 2016 , 18, 163-167	0	1
40	Dose Modification of Antidiabetic Agents in Patients with Type 2 Diabetes Mellitus and Heart Failure. <i>Indian Journal of Endocrinology and Metabolism</i> , 2017 , 21, 618-629	1.7	2
39	Alimentäres System und Stoffwechsel. 2018 , 13-70		
38	Mechanisms of cardiovascular protection of non-insulin antidiabetic medications. <i>Diabetes Mellitus</i> , 2018 , 21, 376-385	1.6	
37	Metformin for Cardiovascular Protection, Inflammatory Bowel Disease, Osteoporosis, Periodontitis, Polycystic Ovarian Syndrome, Neurodegeneration, Cancer, Inflammation and Senescence: What Is Next?. <i>ACS Pharmacology and Translational Science</i> , 2021 , 4, 1747-1770	5.9	3
36	Heart Failure in Diabetes Mellitus: An Updated Review. <i>Current Pharmaceutical Design</i> , 2020 , 26, 5933-5952	5.3	1
35	Mechanisms underlying diabetic cardiomyopathy: From pathophysiology to novel therapeutic targets. <i>Conditioning Medicine</i> , 2020 , 3, 82-97	1.4	2
34	Pharmacological treatment of type 2 diabetes in elderly patients with heart failure: randomized trials and beyond. <i>Heart Failure Reviews</i> , 2021 , 1	5	3
33	[The agreed experts' position of the Eurasian Association of Therapists on tactics of management of patients with comorbid pathology infected with SARS-Cov-2]. <i>Terapevticheskii Arkhiv</i> , 2020 , 92, 108-124	0.9	5
32	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA). <i>ESC European Journal of Heart Failure</i> , 2020 , 21, 1-131	12.3	50
31	Metformin and the heart: Update on mechanisms of cardiovascular protection with special reference to comorbid type 2 diabetes and heart failure.. <i>Metabolism: Clinical and Experimental</i> , 2022 , 130, 155160	12.7	3
30	Effects of Metformin in Heart Failure: From Pathophysiological Rationale to Clinical Evidence.. <i>Biomolecules</i> , 2021 , 11,	5.9	7
29	Metformin: Expanding the Scope of Application-Starting Earlier than Yesterday, Canceling Later.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	1
28	Review of non-insulin antidiabetic pharmacotherapy in patients with heart failure diabetes mellitus in the Czech Republic in 2018. <i>Cor Et Vasa</i> , 2022 , 64, 20-24	0.3	0
27	Role of Primary Care Clinicians in the Management of Patients With Type 2 Diabetes and Cardiorenal Diseases. <i>Clinical Diabetes</i> ,	2.9	
26	Insulin treatment in patients with diabetes mellitus and heart failure in the era of new antidiabetic medications.. <i>BMJ Open Diabetes Research and Care</i> , 2022 , 10,	4.5	0

25	Management of Type 2 Diabetes in Stage C Heart Failure with Reduced Ejection Fraction.. <i>Cardiac Failure Review</i> , 2022 , 8, e10	4.2	
24	Pathophysiology and Treatment of Diabetic Cardiomyopathy and Heart Failure in Patients with Diabetes Mellitus.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	3
23	Co-administration of hydrogen and metformin exerts cardioprotective effects by inhibiting pyroptosis and fibrosis in diabetic cardiomyopathy.. <i>Free Radical Biology and Medicine</i> , 2022 , 183, 35-50	7.8	0
22	Cellular interplay between cardiomyocytes and non-myocytes in diabetic cardiomyopathy.. <i>Cardiovascular Research</i> , 2022 ,	9.9	0
21	Cardiovascular outcomes associated with treatment of type 2 diabetes in patients with ischaemic heart failure.. <i>ESC Heart Failure</i> , 2022 ,	3.7	0
20	Guía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica. <i>Revista Española De Cardiología</i> , 2022 ,	1.5	1
19	Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association. <i>Diabetes Care</i> ,	14.6	8
18	Influence of diabetes on mortality and ICD therapies in ICD recipients: a systematic review and meta-analysis of 162,780 patients. 2022 , 21,		
17	Metformin treatment is associated with improved outcome in patients with diabetes and advanced heart failure (HFREF). 2022 , 12,		2
16	Association between serum insulin levels and heart failure-related parameters in patients with type 2 diabetes and heart failure treated with canagliflozin: a post-hoc analysis of the randomized CANDLE trial. 2022 , 21,		
15	Advances in metformin for the treatment of non-alcoholic fatty liver disease in children. 1-15		0
14	Effect of metformin on left ventricular mass and functional parameters in non-diabetic patients: a meta-analysis of randomized clinical trials. 2022 , 22,		1
13	The role of microRNAs in the pathophysiology, diagnosis, and treatment of diabetic cardiomyopathy.		1
12	Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes.		0
11	A blast from the past: To tame time with metformin. 2022 , 208, 111743		0
10	Pharmacotherapy of type 2 diabetes: An update and future directions. 2022 , 137, 155332		3
9	Inhibition of Toll-like Receptor-4 expression for amelioration of myocardial injury in diabetes: A meta-analysis. 2022 , 77, 100137		0
8	A consensus statement from the Japan Diabetes Society (JDS): a proposed algorithm for pharmacotherapy in people with type 2 diabetes.		0

- 7 A consensus statement from the Japan Diabetes Society: A proposed algorithm for pharmacotherapy in people with type 2 diabetes. ○
- 6 Therapeutic Potential of Metformin in Diabetes Mellitus-Related Cardiovascular Complications. ○
- 5 Evaluation and Management of Patients With Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement. **2023**, 5, 1 2
- 4 Heart failure and diabetes: Clinical significance and epidemiology of this two-way association. ○
- 3 Swiss recommendations of the Society for Endocrinology and Diabetes (SGED/SSED) for the treatment of type 2 diabetes mellitus (2023). **2023**, 153, 40060 ○
- 2 Treatment of type 2 diabetes patients with heart conditions. 1-11 ○
- 1 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction. **2023**, ○